Latest News for PLX
Protalix BioTherapeutics reported weaker FY25 results but issued robust FY26 revenue guidance of $78–83 million, well above consensus. PLX's growth thesis centers on Elfabrio's EU approval and once-every-4-weeks dosing, offering a clear competitive and patient adherence advantage. Chiesi's contribution is expected to exceed 50% revenue growth in 2026, improving margin mix and earnings predictability despite…
American and European households may be growing wealthier at a similar pace, but the composition of that wealth is strikingly different, and those...
Tesla Inc (NASDAQ:TSLA) CEO Elon Musk on Thursday shared an update on the company’s semiconductor plans, indicating that the firm may “tape out” its...
Protalix BioTherapeutics, Inc. (PLX) Q4 2025 Earnings Call Transcript
Protalix Biotherapeutics Inc (NYSE-A:PLX, FRA:PBDA) reported its 2025 financial results and outlined recent regulatory, clinical and commercial developments, including a new European approval for its Fabry disease therapy and updated guidance for 2026. "2025 was a year of meaningful progress for Protalix, marked by strong commercial execution with our partners and important advances and strategic direction across…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PLX.
U.S. House Trading
No House trades found for PLX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.